Cancer-associated Thrombosis
Conditions
Brief summary
The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is: • Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic dosing after 6-month treatment of anticoagulant? The medical record data of participants who's already received for at least 6-month anticoagulant treatment upon regular medical care for CAT will be collected and analyzed about their recurrent thrombosis, anticoagulant related bleeding, and survival outcome.
Detailed description
Adult patients aged ≥18 years with histopathological confirmed cancer, treated at Thammasat University Hospital and Panyananthaphikkhu Chonprathan Medical Center between January 2012 and December 2022, were eligible for inclusion. Patients were initially screened using ICD-10 diagnostic codes C00-D009 for malignancy in conjunction with codes for venous thromboembolism (I82.-, other venous embolism and thrombosis; K55.0, mesenteric vein thrombosis; I82.0, hepatic vein thrombosis; K75.1, phlebitis of the portal vein; and I26.-, pulmonary embolism). Eligible patients required to have a radiologically confirmed diagnosis of cancer-associated thrombosis (CAT) and to have received anticoagulation therapy for at least six months. Clinical data were extracted from the Computerized Provider Order Entry (CPOE) system.
Interventions
DRUGAnticoagulant
warfarin at therapeutic level (INR 2-3), Low molecular weight heparin (LMWH) DOAC
Sponsors
Thammasat University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Here's a polished version of your Inclusion and
Exclusion criteria
section with grammar, spelling, and phrasing corrected for clarity and formal research style: Inclusion Criteria * Adult patients aged ≥18 years * Histopathologically confirmed cancer * Radiologically confirmed diagnosis of cancer-associated thrombosis (CAT) * Received anticoagulation therapy for at least six months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrent thrombosis | After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025. | cumulative incidence of recurrent thrombosis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anticoagulant related bleeding | After completing 6-month of treatment to the time that anticoagulant stop or bleeding occurred through study completion, at the end of December 2025. | cumulative incidence of bleeding |
| Overall survival | The time from VTE diagnosis to last follow up or die through study completion, at the end of December 2025. | Overall survival |
Outcome results
None listed